Archive · 20 Aug 2026
Parliament Panel Urges Deadline For Medicine Trade Margin Caps
A parliamentary committee wants the government to decide quickly how much profit medicine sellers can add to drug prices.
This plan is called trade margin rationalisation.
It would limit the mark-ups charged by distributors and chemists.
The goal is to make some expensive medicines cheaper for patients.
The government has discussed the plan for more than five years but has not set a decision date.
Small pharmaceutical companies worry the plan could hurt their businesses and jobs.
They also fear some remote areas might receive fewer medicines.
The government has already tested similar limits on some cancer medicines and Covid-related devices.
A parliamentary committee urged the Department of Pharmaceuticals to set a deadline for finalising trade margin rationalisation.
Trade margin rationalisation would limit distributor and retailer mark-ups on medicines before they reach patients.
The policy has remained unresolved for more than five years, with no government timeline set.
The approach could reduce costs for expensive medicines, including some cancer drugs, by limiting supply-chain margins.
Pharmaceutical MSMEs warned broad trade-margin caps could cause job losses and reduce medicine access in remote areas.
- Who
- The standing committee on chemicals and fertilisers, the Department of Pharmaceuticals, pharmaceutical manufacturers, and MSME associations.
- What
- The committee urged the Department of Pharmaceuticals to finalise a permanent trade margin rationalisation framework within a clearly defined timeframe.
- When
- The recommendation was reported on August 20, 2026; the policy has been unresolved for more than five years.
- Where
- The proposed framework would apply to medicine sales in India.
- Why
- The committee wants medicines to become more affordable by limiting distributor and retailer mark-ups, while industry groups have raised concerns about business viability and medicine access.
Affordability and consumer protection
Industry and access concerns
Need for a deadline
Affordability and consumer protection
The parliamentary committee says prolonged consultations should not delay affordable medicines and wants the framework finalised within a clearly defined timeframe.
Industry and access concerns
The Department of Pharmaceuticals says the policy remains under active examination and has not committed to a timeline.
Effect on medicine prices
Affordability and consumer protection
Capping distributor and retailer margins could reduce prices for expensive medicines without necessarily reducing manufacturers' ex-factory prices.
Industry and access concerns
MSME pharmaceutical associations argue that applying the framework broadly could damage their business models.
Access and employment
Affordability and consumer protection
Supporters say controlling excessive supply-chain mark-ups could reduce patients' out-of-pocket costs, particularly for high-priced medicines.
Industry and access concerns
MSME groups warn of job losses and potentially reduced medicine availability in remote areas.
- Policy
- Trade margin rationalisation would cap the profit added by distributors and retailers to medicine prices.
- Committee
- The standing committee on chemicals and fertilisers made the recommendation in its 33rd report.
- Government position
- The Department of Pharmaceuticals said there is no set timeframe for integrating TMR into DPCO, 2013.
- Previous pilot
- TMR was tested on 42 high-priced anticancer medicines and six Covid-related devices.
- MSME concerns
- Pharmaceutical MSME associations said broad TMR could cause employment losses and reduce medicine outreach to remote areas.
- Sector estimate
- The department estimates about 7,500 pharmaceutical MSMEs account for roughly 10% of market size.
- Pricing authority
- The National Pharmaceutical Pricing Authority currently fixes prices using market data; existing rules do not provide for cost-audit data.